Interviews

Chris Johnson, MBA, explains how retail-based pediatric clinics and smart tech can expand Medicaid access and streamline visits.

Marc P. Bonaca, MD, MPH, and Josephine Harrington, MD, discuss the clinical value of the uACR test and why it remains underutilized.

Advanced therapies are pressuring reimbursement and necessitating real-world durability data and new payment models, said Fran Gregory, PharmD.

Karen Fancher, PharmD, BCOP, emphasizes a pharmacist’s pivotal role in CLL care through communication, adherence strategies, and bridging patients with medical teams.

Pharmacy innovation—from automation to cell and gene therapy—has moved from future promise to present reality, says Cencora's Ryan Telford, PharmD.

Rose Gerber, MS, explains how listening, personal experience, and small steps can transform patients into powerful advocates for their own care.

Lekan Ajayi, PharmD, explains how remote therapy monitoring keeps patients with cancer on track with their care and reduces emergency visits.

New research incorporating Flatiron Health and SEER data, confirms community oncology care matches or beats other settings, says Diana Verrilli, MS, Navista.

Based on their findings, the 2 experts suggested that tiered benefit design may already strongly influence consumer choices.

Drug pricing transparency and easy discounts cut abandoned prescriptions, as federal policies put pressure on pharma, says Laura Jensen of GoodRx.

Justin Favaro, MD, discusses independent oncology models, ACA challenges, and strategies to reduce health care costs at IVBM Charlotte 2026.

Community oncology delivers top-tier cancer care close to home, said Nicolas Ferreyros, COA, championing research, advocacy, and innovation to prove it.

COA’s Christine Pfaff, RPh, MBA, highlights clinical and operational innovation, AI adoption, and practice-sharing as keys to advancing community oncology care.

COA's annual conference hits Orlando April 28, focusing on AI, targeted therapy innovation, and state-level oncology advocacy, explains cochair Johnetta Blakely, MD, MS, MMHC.

Phase 3 TETON-1 trial shows inhaled treprostinil improves FVC in IPF, signaling a potential new antifibrotic option.

Bispecific antibodies are delivering unprecedented response rates in multiple myeloma, offering fast, flexible options alongside CAR T-cell therapy, explains Prerna Mewawalla, MD.

Pediatric care deserts push Medicaid families into costly ED visits; learn how primary care access gaps fuel chronic issues and spending.

Fran Gregory, PharmD, MBA, explains why community providers can't go it alone—and how specialty pharmacy is stepping in to carry the load.

Rani Bansal, MD, explores what's driving the surge in breast cancer in young women and why earlier, risk-based screening matters.

AMCP 2026 spotlighted oncology innovation, AI, and payer strategies, with KOL insights on cost, access, and evolving managed care trends.

TETON-1 data show inhaled treprostinil improves FVC and reduces worsening in IPF, supporting a potential new treatment and combo strategy.

Experts from AMCP emphasize the importance of drug-adjacent early detection tests and screening ability to improve patient outcomes.

Experts from AMCP discuss the real-world evidence on GLP-1 usage and health care spending.

Daryl Pritchard, PhD, discusses the challenges to implementing biomarker testing that would advance precision medicine and improve patient outcomes in oncology.

Alyson Moadel-Robblee, PhD, outlines how the BOLD Program proactively supports cancer caregivers through community-based care.

At AMCP 2026, Kelsea Aragon, PharmD, discussed PrEP coverage, long-acting injectables, and payer strategies to improve HIV treatment access and adherence.

Despite high rates of grade 3/4 infection, teclistamab was granted full approval by the FDA. Ajay K. Nooka, MD, speaks on how to optimally treat this adverse effect.

Patty Taddei-Allen, PharmD, MBA, examines how co-pay accumulators, maximizers, and AFPs shift costs, impact rebates, and create access challenges for patients.